‘The #atopic_dermatitis market is heating up! #Sanofi is gearing up to challenge #Dupixent's dominance. What new treatments are on the horizon?’ Sanofi is also advancing in the AD arena with ...

including atopic dermatitis (AD), in which it is considered the gold standard, says GlobalData, a data and analytics company. “Having Dupixent as the gold standard for AD, Sanofi has set a high ...

This achievement further emphasises the drug’s efficacy across multiple indications, including atopic dermatitis (AD), in which it is considered the gold standard. The use of Dupixent in AD has ...

including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE) and other I&I indications, today announced the first ...

Apogee Therapeutics, Inc., a clinical-stage biotechnology company, announced the first patient has been dosed in the Part B portion of the phase 2 APEX clinical trial of APG777 in patients with ...

This achievement further emphasises the drug’s efficacy across multiple indications, including atopic dermatitis (AD), in which it is considered the gold standard. The use of Dupixent in AD has set a ...

including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE) and other I&I indications, today announced the first patient ...

including atopic dermatitis (AD), in which it is considered the gold standard, says pharma analytics company GlobalData. Filippos Maniatis, healthcare analyst at GlobalData, commented: “Having ...

Sanofi’s new atopic dermatitis treatment Dupixent has gained EU approval ... in clinical trials improving atopic dermatitis (AD) in moderate-to-severe patients, where it is the first systemic ...

Lilly’s drug becomes an oral alternative to Sanofi and Regeneron’s biologic therapy Dupixent (dupilumab), which was recommended as a second-line option for moderate to severe atopic dermatitis ...

Atopic dermatitis is a chronic inflammatory skin disease affecting a growing number of people worldwide. Marked by persistent ...